Adm1n at 02:34, 15 February 2015

2015-02-15T02:34:35Z

Adm1n: Created page with "ADBICA is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale..."

2015-02-15T02:33:51Z

Created page with "ADBICA is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale..."

New page

ADBICA is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like [[SDB-00]]1 and [[STS-135]]. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. Nothing is known of the pharmacological activity of ADBICA in humans or other animals.

==See also==

* [[AB-FUBINACA]]
* [[ADB-FUBINACA]]
* [[APINACA]]
* [[PF-03550096]]
* [[SDB-001]]
* [[STS-135 (drug)|STS-135]]

← Older revision		Revision as of 02:34, 15 February 2015
Line 1:		Line 1:
−	ADBICA is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like [[SDB-00]]1 and [[STS-135]]. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. Nothing is known of the pharmacological activity of ADBICA in humans or other animals.	+	ADBICA is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like [[SDB-001]] and [[STS-135]]. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. Nothing is known of the pharmacological activity of ADBICA in humans or other animals.

	==See also==		==See also==

ADBICA - Revision history

Adm1n at 02:34, 15 February 2015

Adm1n: Created page with "ADBICA is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale..."